Open Collections

UBC Faculty Research and Publications

New drugs VIII Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 51 reviews the evidence for new drugs telithromycin, ezetimibe, topical pimecrolimus, and tacrolimus. Conclusions: telithromycin is of similar efficacy to but has more adverse effects than clarithromycin, the one macrolide to which it has been compared. Ezetimibe alone or when added to a statin lowers LDL cholesterol by 16 to 18% in 3-month trials. It is unknown whether ezetimibe therapy for longer time periods will be beneficial or harmful. Pimecrolimus has not been compared with corticosteroids in children and has a therapeutic disadvantage versus corticosteroids in adults. Tacrolimus was more efficacious in children than the lowest potency corticosteroid, 1% hydrocortisone acetate. Tacrolimus has a therapeutic disadavantage versus corticosteroids in adults.

Item Metadata

Title
New drugs VIII
Alternate Title
Therapeutics Letter 51
Creator
Therapeutics Initiative (University of British Columbia)
Date Issued
2004-03
Description
Therapeutics Letter 51 reviews the evidence for new drugs telithromycin, ezetimibe, topical pimecrolimus, and tacrolimus. Conclusions: telithromycin is of similar efficacy to but has more adverse effects than clarithromycin, the one macrolide to which it has been compared. Ezetimibe alone or when added to a statin lowers LDL cholesterol by 16 to 18% in 3-month trials. It is unknown whether ezetimibe therapy for longer time periods will be beneficial or harmful. Pimecrolimus has not been compared with corticosteroids in children and has a therapeutic disadvantage versus corticosteroids in adults. Tacrolimus was more efficacious in children than the lowest potency corticosteroid, 1% hydrocortisone acetate. Tacrolimus has a therapeutic disadavantage versus corticosteroids in adults.
Subject
Child; Adult; Cholesterol, LDL; Ezetimibe; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pimecrolimus; Tacrolimus; Telithromycin
Genre
Other
Type
Text
Language
eng
Notes
The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available
2023-06-20
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0433630
URI
http://hdl.handle.net/2429/85040
Affiliation
Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International